257 related articles for article (PubMed ID: 37345219)
1. DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.
Kagan AB; Garrison DA; Anders NM; Webster JA; Baker SD; Yegnasubramanian S; Rudek MA
Clin Transl Sci; 2023 Aug; 16(8):1309-1322. PubMed ID: 37345219
[TBL] [Abstract][Full Text] [Related]
2. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?
Brunner AM; Fell G; Steensma DP
Blood Adv; 2022 May; 6(9):2854-2866. PubMed ID: 35143613
[TBL] [Abstract][Full Text] [Related]
3. Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR; Kogan AA; Bentzen SM; Mi T; Lapidus RG; Duong VH; Emadi A; Niyongere S; O'Connell CL; Youngblood BA; Baylin SB; Rassool FV
Clin Cancer Res; 2022 Apr; 28(7):1313-1322. PubMed ID: 35091444
[TBL] [Abstract][Full Text] [Related]
4. Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
Ku Y; Park JH; Cho R; Lee Y; Park HM; Kim M; Hur K; Byun SY; Liu J; Lee YS; Shum D; Shin DY; Koh Y; Cho JY; Yoon SS; Hong J; Kim Y
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762305
[TBL] [Abstract][Full Text] [Related]
5. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
6. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
Boddu P; Kantarjian H; Garcia-Manero G; Ravandi F; Jabbour E; Borthakur G; Daver N; Pemmaraju N; Pierce S; Cortes J; Kadia TM
Leuk Lymphoma; 2018 Apr; 59(4):1012-1015. PubMed ID: 28838278
[No Abstract] [Full Text] [Related]
7. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
8. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
[TBL] [Abstract][Full Text] [Related]
9. The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression.
Zhang X; Li B; de Jonge N; Björkholm M; Xu D
Oncotarget; 2015 Mar; 6(7):4888-900. PubMed ID: 25682873
[TBL] [Abstract][Full Text] [Related]
10. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
Short NJ; Kantarjian H
Am J Hematol; 2022 Dec; 97(12):1616-1626. PubMed ID: 35871436
[TBL] [Abstract][Full Text] [Related]
13. The role of hypomethylating agents in the treatment of elderly patients with AML.
Al-Ali HK; Jaekel N; Niederwieser D
J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
[TBL] [Abstract][Full Text] [Related]
14. Decitabine--bedside to bench.
Oki Y; Aoki E; Issa JP
Crit Rev Oncol Hematol; 2007 Feb; 61(2):140-52. PubMed ID: 17023173
[TBL] [Abstract][Full Text] [Related]
15. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
[TBL] [Abstract][Full Text] [Related]
16. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Tsujioka T; Yokoi A; Uesugi M; Kishimoto M; Tochigi A; Suemori S; Tohyama Y; Tohyama K
Exp Hematol; 2013 Feb; 41(2):189-97. PubMed ID: 23085465
[TBL] [Abstract][Full Text] [Related]
17. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Feld J; Tremblay D; Navada SC; Silverman LR
Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
[TBL] [Abstract][Full Text] [Related]
18. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
Santini V; Ossenkoppele GJ
Crit Rev Oncol Hematol; 2019 Aug; 140():1-7. PubMed ID: 31153036
[TBL] [Abstract][Full Text] [Related]
19. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD
Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154
[TBL] [Abstract][Full Text] [Related]
20. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
